Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Tibsovo Approved for Treatment of Acute Myeloid Leukemia
Medical Advances in Leukemia Research
Treatment National Cancer Institute
Cancer Currents: An NCI Cancer Research Blog - NCI
Treatment National Cancer Institute
PDF) Emerging and Future Targeted Therapies for Pediatric Acute
Summary of in vitro and in vivo data of given compounds and
Cancer Currents: An NCI Cancer Research Blog - NCI
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
de
por adulto (o preço varia de acordo com o tamanho do grupo)
